Literature DB >> 26040439

Procalcitonin and Pentraxin-3: Current biomarkers in inflammation in white coat hypertension.

H Yavuzer1, M Cengiz1, S Yavuzer1, M Rıza Altıparmak2, B Korkmazer3, H Balci4, A L Yaldıran1, H Uzun5.   

Abstract

An association has been described between inflammation and the progression of hypertension (HT) and is shown with several biochemical parameters. Our aim was to examine the distribution of the serum procalcitonin (PCT), pentraxin (PTX)-3 and interleukin (IL)-33 levels and their relationship with carotid intima-media thickness (CIMT) in subjects with white coat HT (WCH), HT and normotension (NT) groups. Thirty-three patients with HT, 33 patients with WCH and 33 healthy subjects were enrolled in this study. PCT, PTX-3 and C-reactive protein (CRP) levels significantly increased in the HT group compared with the NT group. In addition, PCT and CRP levels were significantly higher in the WCH group than in the NT group. CIMT measurements were significantly higher in the WCH and HT groups than in the NT group. In the HT and WCH groups, there were significant positive correlations between PTX-3, PCT and CRP. In the WCH group, PTX-3 and PCT levels were significantly positively correlated with CIMT. PCT had area under the curve value of 0.817 which demonstrates its sufficiency to distinguish WCH from NT individuals. Our results suggest that in subjects with WCH and HT, which are characterized by increased cardiovascular risk, PTX-3 and PCT levels in the HT group and PCT levels in the WCH group are significantly and consistently higher than normotensives. Systemic inflammation moderately occurs in the WCH and HT groups. PCT monitoring may be a useful biomarker in inflammation related to atherosclerosis and early stage HT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26040439     DOI: 10.1038/jhh.2015.59

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  35 in total

1.  Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome.

Authors:  H E Ataoğlu; F Yilmaz; I Uzunhasan; F Cetin; Lü Temiz; Y E Döventaş; A Kaya; M Yenigün
Journal:  J Int Med Res       Date:  2010 Jan-Feb       Impact factor: 1.671

2.  Inflammation and hypertension: the search for a link.

Authors:  Paolo Pauletto; Marcello Rattazzi
Journal:  Nephrol Dial Transplant       Date:  2006-02-07       Impact factor: 5.992

3.  How common is white coat hypertension?

Authors:  T G Pickering; G D James; C Boddie; G A Harshfield; S Blank; J H Laragh
Journal:  JAMA       Date:  1988-01-08       Impact factor: 56.272

4.  Is C-reactive protein an independent risk factor for essential hypertension?

Authors:  L E Bautista; P López-Jaramillo; L M Vera; J P Casas; A P Otero; A I Guaracao
Journal:  J Hypertens       Date:  2001-05       Impact factor: 4.844

5.  Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease.

Authors:  Christoph R Sinning; Jan-Malte Sinning; Andreas Schulz; Renate B Schnabel; Edith Lubos; Philipp S Wild; Jana Papassotiriou; Andreas Bergmann; Stefan Blankenberg; Thomas Munzel; Christoph Bickel
Journal:  Circ J       Date:  2011-03-03       Impact factor: 2.993

6.  High sensitivity C-reactive protein as an independent risk factor for essential hypertension.

Authors:  Ki Chul Sung; Jung Yul Suh; Bum Soo Kim; Jin Ho Kang; Hyang Kim; Man Ho Lee; Jung Ro Park; Sun Woo Kim
Journal:  Am J Hypertens       Date:  2003-06       Impact factor: 2.689

7.  C-reactive protein and the risk of developing hypertension.

Authors:  Howard D Sesso; Julie E Buring; Nader Rifai; Gavin J Blake; J Michael Gaziano; Paul M Ridker
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

8.  Association of hypertension with coexistence of abnormal metabolism and inflammation and endothelial dysfunction.

Authors:  Mingzhi Zhang; Guiyan Wang; Aili Wang; Weijun Tong; Yonghong Zhang
Journal:  Blood Press       Date:  2012-12-04       Impact factor: 2.835

9.  Procalcitonin increase after endotoxin injection in normal subjects.

Authors:  P Dandona; D Nix; M F Wilson; A Aljada; J Love; M Assicot; C Bohuon
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

10.  Low-grade inflammation in white-coat hypertension.

Authors:  Mustafa Ozdogan; Hakan Bozcuk; Erkan Coban
Journal:  Med Sci Monit       Date:  2007-12
View more
  2 in total

1.  The responses of the inflammatory marker, pentraxin 3, to dietary sodium and potassium interventions.

Authors:  Jia-Wen Hu; Yang Wang; Chao Chu; KeKe Wang; Yu Yan; Wenling Zheng; Qiong Ma; Jian-Jun Mu
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-27       Impact factor: 3.738

2.  Subclinical Organ Damage in White-Coat Hypertension: The Possible Role of Cystatin C.

Authors:  Emmanuel Androulakis; Nikolaos Papageorgiou; Eirini Lioudaki; Evaggelos Chatzistamatiou; Effimia Zacharia; Ioannis Kallikazaros; Dimitris Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-21       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.